| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Feb 2026 | 5 Feb 2026 |
| Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve unaudited standalone & consolidated financial results of the Company for the quarter and nine months ended on December 31 2025. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, 11th February, 2026 have inter-alia, considered and approved: 1. The Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2025. Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Deloitte Haskins & Sells LLP, Statutory Auditors of the Company is enclosed herewith 2. Investment of upto USD 15,000 for incorporating a wholly owned subsidiary in Chile, LATAM region. (As Per BSE Announcement Dated on 11.02.2026) | ||
| Board Meeting | 21 Jan 2026 | 15 Jan 2026 |
| Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2026 inter alia to consider and approve the proposal for raising of funds by way of issue of one or more instrument/ securities including equity shares warrants or securities convertible into equity shares of the Company or debt securities by way of rights issue preferential issue on a private placement basis qualified institutional placement or through any other methods or combinations thereof as may be considered appropriate in accordance with applicable laws and subject to any regulatory/ statutory approvals as may be required. Please find enclosed the outcome of Board Meeting held on 21.01.2026. (As per BSE announcement dated on : 20.01.2026) | ||
| Board Meeting | 12 Nov 2025 | 5 Nov 2025 |
| Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2025 The Board of Directors of the Company at their meeting held on 12th November, 2025 have considered and approved the unaudited financial results (Standalone and Consolidated) of the company for the quarter and half-year ended 30th September, 2025 (As Per BSE Announcement Dated on 12.11.2025) | ||
| Board Meeting | 19 Sep 2025 | 19 Sep 2025 |
| Pursuant to Regulation 30 of SEBI (LODR) Regulations, please find enclosed the disclosure regarding the re-appointment of Whole-time directors of the Company. | ||
| Board Meeting | 7 Aug 2025 | 31 Jul 2025 |
| Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2025. The Board of Directors of the company at their meeting held on 07th August, 2025 have inter-alia considered and approved the unaudited standalone & consolidated financial results for the quarter ended 30th June, 2025 (As Per BSE Announcement Dated on: 07/08/2025) | ||
| Board Meeting | 20 May 2025 | 14 May 2025 |
| Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve Audited financial results for the quarter and year ended 31st March 2025 The Outcome of the Board Meeting held on 20th May, 2025 is enclosed herewith. (As Per BSE Announcement Dated on :20.05.2025) | ||
| Board Meeting | 28 Apr 2025 | 28 Apr 2025 |
| In compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you about the outcome of the Board Meeting held on 28/04/2025 | ||
| Board Meeting | 28 Mar 2025 | 28 Mar 2025 |
| Disclosure under Regulation 30 - Change in management Disclosure under Regulation 30 - Acquisition Disclosure under Regulation 30 - Appointment of Secretarial Auditor | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
